Cadrenal Therapeutics
Robert Lisicki currently serves as the Chief Executive Officer and President of Zura Bio Limited (Nasdaq: ZURA) since January 2024. Additionally, Robert holds a position on the Board of Directors for Cadrenal Therapeutics, Inc. and Adiso Therapeutics. Previously, Robert was the CEO and a Board Member at InCarda Therapeutics until March 2023, and held the role of Executive Vice President and Chief Commercial Officer at Arena Pharmaceuticals from November 2018 to March 2022, where responsibilities included global scaling and development of novel agents. Other notable positions include General Manager and Vice President at Regeneron, Senior Vice President and Chief Commercial Officer at Daiichi Sankyo, and Vice President and General Manager at Amgen, where Robert contributed to substantial revenue growth and oversight of significant commercial operations. Robert's career began at The Janssen Pharmaceutical Companies of Johnson & Johnson, where Robert was involved in sales and marketing leadership.
This person is not in any teams
Cadrenal Therapeutics
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment.